Innate Pharma SA (IPHYF) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Jun 1, 2026

Innate Pharma S.A. (NASDAQ:IPHA) is a French biotechnology company founded in 1999 and headquartered in Marseille, France. The company went public on NASDAQ in October 2019. Innate Pharma specializes in discovering, developing, and commercializing therapeutic antibodies primarily focused on oncology treatments, with a particular emphasis on leveraging the immune system to fight cancer through innovative approaches including natural killer (NK) cell engagers and antibody-drug conjugates.

Ask drillr about Innate Pharma SA →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

6.22M

Net Income (TTM)

−93.57M

Op. CF (TTM)

−88.69M

Latest newsMore news →

Innate Pharma's strategic partnership with Sobi to license lacutamab in T-cell lymphoma became effective after antitrust waiting periods expired and closing conditions were met, triggering a USD 75 million payment.4d ago

Innate Pharma S.A. announced an equity raise of EUR 30 million.37d ago

Latest newsMore news →